Related references
Note: Only part of the references are listed.Efficacy and safety of dual intravenous artesunate plus quinine compared to intravenous artesunate for cerebral malaria in a triple blinded parallel multisite randomized controlled trial in Nigerian children: DUAL PAQ TRIAL Protocol
Michael Abel Alao et al.
TRIALS (2021)
Safety and Effectiveness of Intravenous Artesunate for Treatment of Severe Malaria in the United States-April 2019 Through December 2020
Francisca Abanyie et al.
CLINICAL INFECTIOUS DISEASES (2021)
Evidence of Artemisinin-Resistant Malaria in Africa
Betty Balikagala et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Artesunate Versus Quinine: Keeping Our Options Open
Anne E. P. Frosch
CLINICAL INFECTIOUS DISEASES (2020)
Efficacy and Safety of Intravenous Artesunate in Children With Severe Imported Malaria
Elisabetta Venturini et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2020)
Emergence and clonal expansion of in vitro artemisinin-resistantPlasmodium falciparum kelch13R561H mutant parasites in Rwanda
Aline Uwimana et al.
NATURE MEDICINE (2020)
Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany A Retrospective Study
Sabine Belard et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2019)
Poor response to artesunate treatment in two patients with severe malaria on the Thai-Myanmar border
Aung Pyae Phyo et al.
MALARIA JOURNAL (2018)
Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications
Camille Roussel et al.
JOURNAL OF TRAVEL MEDICINE (2017)
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic
Benjamin Blasco et al.
NATURE MEDICINE (2017)
Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study
Florian Kurth et al.
CLINICAL INFECTIOUS DISEASES (2015)
Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis
Thierry Rolling et al.
MALARIA JOURNAL (2013)
Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium
Annemarie R. Kreeftmeijer-Vegter et al.
MALARIA JOURNAL (2012)
Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre
Marcus Eder et al.
PATHOGENS AND GLOBAL HEALTH (2012)
Case Report: Combined Intravenous Treatment with Artesunate and Quinine for Severe Malaria in Italy
Alessandro Bartoloni et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2010)
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
Arjen M. Dondorp et al.
LANCET (2010)
Artemisinin Resistance in Plasmodium falciparum Malaria.
Arjen M. Dondorp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects
Sara Asimus et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
Artesunate versus quinine for treating severe malaria
K. L. Jones et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) probes for human UDP- glucuronosyltransferases
V Uchaipichat et al.
DRUG METABOLISM AND DISPOSITION (2006)
Study of inhibition of CYP2A6 by some drugs derived from quinoline
Y Hirano et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
A comparison of artesunate alone with combined artesunate and quinine in the parenteral treatment of acute falciparum malaria
PN Newton et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2001)
Share Paper
